Latest news with #ShaunakAmin
Business Standard
06-05-2025
- Business
- Business Standard
Alembic Pharma slips after Q4 PAT drops 12% YoY to Rs 157 cr
Alembic Pharmaceuticals declined 4.04% to Rs 867.35 after the company's consolidated net profit declined 12.11% to Rs 156.63 crore in Q4 FY25 as compared with Rs 178.21 crore in Q4 FY24. Revenue from operations grew 16.66% year on year (YoY) to Rs 1,769.64 crore in the quarter ended 31st March 2025. Profit before tax (PBT) was at Rs 191.95 crore in Q4 FY25, up 4.98% from Rs 182.85 crore recorded in the corresponding quarter previous year. EBIDTA grew 9% YoY to Rs 266 crore while EBIDTA margin stood at 16% during the period under review. On the segmental front, API revenue was Rs 342 crore (up 4% YoY). In the Formulations business, India revenue was Rs 545 crore (up 8% YoY), US revenue was Rs 508 crore (up 20% YoY) and Ex-US revenue was Rs 375 crore (up 43% YoY). On full year basis, the companys consolidated net profit fell 5.49% to Rs 582.01 crore despite of 7.12% jump in revenue from operations to Rs 6,672.08 crore in FY25 over FY24. Shaunak Amin, MD, Alembic Pharmaceuticals, said, India-Branded Business displayed improved performance, backed by Specialty therapies. While the Animal Health division continued to outperform through a strong portfolio of trusted brands. By deepening our engagement with healthcare professionals and expanding our product pipeline, we have laid a solid foundation for strong, consistent growth, going forward. Our Ex-US business delivered a strong growth of 43% across all markets whereas the US business grew by 20% during the quarter. Meanwhile, the companys board recommended a dividend of Rs 11 per share having face value of Rs 2 each, subject to approval of the Shareholders at the ensuing annual general meeting (AGM). Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company. The company manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA.
Business Upturn
06-05-2025
- Business
- Business Upturn
Alembic Pharmaceuticals Q4 Results: Revenue rises 16.7% YoY to ₹1,769 crore, Net profit down 11.96% YoY
Alembic Pharmaceuticals Ltd announced its financial results for the fourth quarter of FY25, reporting a mixed set of numbers. The company posted a net profit of ₹157 crore, down 11.8% year-on-year (YoY) from ₹178 crore in Q4FY24. The decline in profit was attributed to higher operating expenses and a dip in EBITDA margins. However, revenue for the quarter rose 16.7% YoY to ₹1,769.6 crore, up from ₹1,517 crore in the same period last year, reflecting continued growth across business segments. EBITDA for the quarter stood at ₹272 crore, up 4.6% YoY from ₹260 crore, but margins contracted to 15.4% compared to 17.1% last year. For the full year FY25, Alembic posted consolidated revenue of ₹6,714.63 crore, marking a 7% growth YoY, while net profit declined 5.3% YoY to ₹583.42 crore, largely due to increased raw material costs and tax outflows. Segment-wise, the India branded business grew 8% YoY to ₹545 crore, and US generics reported 20% YoY growth to ₹508 crore. The Ex-US generics segment showed a robust 43% jump, clocking ₹375 crore. The API business also contributed ₹342 crore, growing 4% YoY. The company received two ANDA approvals and launched four new products in the US during the quarter, boosting its international momentum. Managing Director Shaunak Amin credited the domestic specialty portfolio and global expansion as key performance drivers. Key Highlights: Q4 Net Profit: ₹157 crore (↓11.8% YoY) Q4 Revenue: ₹1,769.6 crore (↑16.7% YoY) Q4 EBITDA: ₹272 crore (↑4.6% YoY) EBITDA Margin: 15.4% vs 17.1% (YoY) FY25 Revenue: ₹6,714.63 crore (↑7% YoY) FY25 Net Profit: ₹583.42 crore (↓5.3% YoY) India Business: ₹545 crore (↑8% YoY) US Generics: ₹508 crore (↑20% YoY) Ex-US Generics: ₹375 crore (↑43% YoY) API Segment: ₹342 crore (↑4% YoY) Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
